Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POWER: Pre-operative Endocrine Therapy to Inform Radiation Decisions in Breast Cancer
NCT04272801Phase 2Active, not recruiting
- Start
- Apr 2020
- Primary completion
- Jun 2024
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tamoxifen, letrozole, anastrozole, exemestane in estrogen receptor-positive breast cancer (ER+). Started Apr 2020; status: active, not recruiting.
02
Drugs
tamoxifenletrozoleanastrozoleexemestane
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT04272801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272801.